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Abstract 
Ebola virus disease was irst described in 1976 originating from the Ebola River in the Demo-
cratic Republic of Congo. Since then, Ebola virus has become an important public health threat 
in Africa, and now it is of great concern worldwide due to the recent outbreaks (9216 cases with 
4555 deaths up to October 20th, 2014), and it is so far the largest and deadliest recorded in his-
tory. Five Ebola virus species have been identiied (including Zaire, Sudan, Ivory Coast, Reston, 
and Bundibugyo Ebola virus), and four of them have proved to be highly pathogenic for both 
human and non-human primates, causing viral hemorrhagic fever with case fatality rates of up 
to 90%, for which no approved therapeutics or vaccines are currently available. Ebola virus in-
fections are characterized by immune suppression and a systemic inlammatory response that 
causes impairment of the vascular, coagulation, and immune systems, leading to multiorgan 
failure and shock, and thus, in some ways, resembling septic shock. The major affected coun-
tries, Sierra Leone, Guinea, Liberia, and Nigeria, have been struggling to contain and to miti-
gate the outbreak. Gene sequencing of the 2014 virus (2014WA) outbreak has demonstrated 98% 
homology with the Zaire Ebola virus, with a 49% case fatality ratio across the affected coun-
tries. In this review the characteristics of the viruses, pathogenesis, diagnosis, treatment, and 
the cases reported in health care workers (HCW) are described, as well as a summary of out-
breaks of the virus since its discovery, including these last two outbreaks in Africa.
© 2014 Revista Medicina Universitaria. Facultad de Medicina UANL. Published by Elsevier México. All rights 
reserved. 
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Introduction
Critical challenges have resulted from infectious diseases, 
including the emergence and reemergence of old and new 
infectious diseases.1 Emerging pathogens can be into two 
categories: microbes newly introduced to humans from oth-
er species, and existing but previously rare human patho-
gens that rise rapidly in prevalence or pathogenicity.2 Their 
appearance is often attributed to human intrusion on animal 
habitats, environmental evolution and deforestation, chang-
ing socioeconomic conditions, increased global connectivity, 
and genetic changes in microorganisms.3 Ebola virus is an 
example of the second category because it was introduced in 
1976,4,5 and possibly considered rare because we lack the 
tools to routinely detect it.3 Ebola, or Ebola virus disease 
(EVD), is a severe, often fatal disease affecting humans and 
nonhuman primates,6 outbreaks of which occur in Africa 
within 10° of the Equator affecting mostly the central part 
of the continent.7,8
Viral genome structure and organization
Ebola virus is a non-segmented negative stranded RNA virus, 
member of the Filoviridae family from the Mononegavirales 
order.9 The Ebola virus has an 80 nm diameter and its length 
can be up to 14 000 nm. The viral genome consists of seven 
genes: nucleoprotein, virion protein (VP) 35, VP40, glyco-
protein, VP30, VP24, and RNA-dependent RNA polymerase 
(L).9,10 The glycoprotein is the only transmembrane surface 
protein and serves for viral attachment to host cells.10,11 The 
ribonucleoprotein complex assists replication, transcrip-
tion,12 particle formation,13 and interferes14 and antagonizes 
interferon signaling.15
Ebola virus species
There are ive identiied Ebola virus species: Zaire, Sudan, Tai 
Forest, Bundibugyo and Reston. Zaire and Sudan Ebola virus-
es were irst isolated in 1976 at the simultaneous outbreaks 
in southern Sudan and northern Zaire, now Democratic Re-
public of Congo (DRC).4,5 Initially the etiological pathogen 
was the same in both regions, but further analyses identiied 
two species.16 The third Ebola virus specie, Tai Forest, was 
isolated from an infected ethnologist who did a necropsy on 
a chimpanzee in the Tai Forest reserve in Ivory Coast, West-
ern Africa.17 The fourth Ebola virus specie, Bundibugyo, was 
identiied in Uganda in 2007.18 The ifth specie, Reston, was 
identiied on infected Cynomolgus monkeys (Macaca fascicu-
laris) imported from the Philippines, and quarantined in Res-
ton, VA, USA.19,20 Reston Ebola virus is not pathogenic to 
humans, only to non-human primates21 and pigs.22
Viral evolution and phylogeny
According to phylogenetic analysis, the Ebola viruses divides 
into ive different branches. The branches of Zaire, Tai For-
est, and Bundibugyo Ebola viruses are grouped together, 
suggesting a common ancestor. The Reston and Sudan Ebola 
viruses share similarly a common ancestor.23 The Zaire Ebola 
viruses are subdivided into ive distinct lineages according 
to different outbreaks. Viruses isolated during 1976 to 1977 
represent the irst lineage. The second lineage is made of 
viruses isolated from 1994 to 1996. The virus isolated in Ga-
bon during 2002 makes the third lineage. Viruses isolated 
during 2007 to 2008 represent the fourth lineage. The vi-
ruses from the 2014 West African outbreak make the ifth 
lineage.24 It is important to note that the Ebola virus from 
this outbreak out-groups the rest of the lineages, suggesting 
an introduction of the virus to the human population.25 In 
contrast, the Zaire Ebola virus from the DRC outbreak 
groups with the second lineage, viruses isolated during 1996 
in Gabon.26 This fact conirms that both outbreaks are not 
related. These indings denote a constant evolution of these 
viruses as expected from the RNA viruses.
Historical outbreaks of Ebola viruses
There have been multiple EVD outbreaks since 1976 which 
are listed chronologically in table 1.27 During the 70’s, DRC 
and Sudan were affected by Zaire and Sudan Ebola viruses 
causing 637 human cases and 454 deaths. There was a 15-
year period where no EVD outbreaks were reported. In 1994 
there was an outbreak in Gabon caused by Zaire Ebola virus. 
In the same year, the Tai Forest Ebola virus was discovered in 
Ivory Coast.17 For the following years, Zaire Ebola virus con-
tinued affecting DRC, Gabon and South Africa. Ebola out-
breaks continued appearing between 2000 and 2004. Sudan 
Ebola virus affected Uganda and Sudan in 2000 and 2004, 
respectively. Zaire Ebola virus affected Gabon and Congo in 
three different outbreaks. The same virus specie was also 
responsible for the outbreaks in DRC in 2007, 2008 while 
Bundibugyo was introduced to Uganda in 2007.18 From 2011 
to 2013, Sudan Ebola virus has affected Uganda. Bundibugyo 
Ebola virus continued causing outbreaks, but this time in 
DRC during 2012.27,28 The case fatality rate of each outbreak 
is different, even between same Ebola virus specie.
Current outbreaks in Africa
Although most previous EVD outbreaks occurred in Central 
Africa, the most recent outbreak started in West Africa. The 
2014 West Africa outbreak is the largest ever observed, both 
by number of cases and geographical extension. Fortunate-
ly, the majority of the cases are concentrated in three coun-
tries in West Africa, with only a small number out of the 
area. Basically, there are two EVD outbreaks occurring si-
multaneously in Africa. The irst one to appear was the out-
break in West Africa, in Guinea during December 2013, and 
was conirmed by the World Health Organization in March 
2014. The second one occurred in western DRC during Au-
gust 2014.28
The current outbreaks are both due to Zaire Ebola virus,25 
but they are not related.26 The West African outbreak start-
ed in December 2013 in Guinea25 and spread into Liberia in 
March 2014, Sierra Leone in May, Nigeria in late July and 
Senegal in September.29 As of October 14, 2014, 9216 cases 
and 4555 deaths have been reported in seven affected coun-
tries (Guinea, Liberia, Nigeria, Senegal, Sierra Leone, Spain, 
and the United States of America).29 According to the World 
Health Organization Ebola Response Roadmap structure, 
Guinea, Liberia, and Sierra Leone are countries with wide-
spread and intense transmission. Countries with an initial 
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case or cases, or with localized transmission are: Nigeria, 
Senegal, Spain, and the United States of America.29 WHO of-
icially declared the EVD outbreak over in Senegal due to a 
second EVD-negative sample from the single conirmed case 
in Senegal on September 5 (42 days ago).30 In this recent 
outbreak, by October 17, the case fatality rate was 49.4%, 
when all countries were included, and this rate was consis-
tent among Guinea, Liberia and Sierra Leone.29 Neverthe-
less, the case fatality rate will vary as the human cases and 
deaths increase throughout time. The most recent account 
of cases as of October 20th, 2014 reported: 9216 total cas-
es, 4218 laboratory-conirmed cases and 4555 total deaths. 
Concerning DRC outbreak, as of October 9, 2014 there have 
been 68 cases of EVD, 49 reported deaths and 72% case fa-
tality rate.29
Pathogenesis
Information about the pathology and pathogenesis of Ebola 
virus infections in man is scarce. Yet, comprehensive studies 
have been done in animals. Guinea pigs and mice have been 
used to study Ebola hemorrhagic fever.31-33 Since isolates of 
Ebola virus obtained from primates do not typically produce 
severe disease in rodents on initial exposure, serial adapta-
tion is needed to produce a uniformly lethal infection. How-
ever, the disease pathogenesis recorded in rodents is less 
accurate.34,35
Route of infection
Ebola virus enters the host through mucosal surfaces, 
breaks, and abrasions in the skin, or by parenteral introduc-
tion. Most human infections in outbreaks seem to occur by 
direct contact with infected patients or corpses.28,36,37 Infec-
tious virus particles or viral RNA have been detected in se-
men, genital secretions,38,39 and in skin of infected 
patients;40 they have also been isolated from skin, body lu-
ids, and nasal secretions of experimentally infected non-
human primates.41,42
Laboratory exposure through needle sticks and blood have 
been reported.43 Butchering of a chimpanzee and bats for 
food were linked to outbreaks of Zaire Ebola virus in Gabon 
and DRC, respectively.44,45 The route of transmission of Ebola 
viruses seems to affect the disease course and outcome. 
Table 1 Ebola virus disease outbreaks throughout time in Africa from 1976 to 2014 reported by CDC and WHO until October 
13th, 2014
Year Country Virus species Human cases Deaths Case fatality (%)
1976 DRC Zaire 318 280 88
1976 Sudan Sudan 284 151 53
1977 Zaire Zaire 1 1 100
1979 Sudan Sudan 34 22 65
1994 Gabon Zaire 52 31 60
1994 Ivory Cost Tai Forest 1 0 0
1995 DRC Zaire 315 250 81
1996 Gabon Zaire 37 21 57
1996 Gabon Zaire 60 45 74
1996 South Africa Zaire 2 1 50
2000 Uganda Sudan 425 224 53
2002 Gabon Zaire 65 53 82
2002 Congo Zaire 57 43 75
2003 Congo Zaire 143 128 89
2003 Congo Zaire 35 29 83
2004 Sudan Sudan 17 7 41
2007 DRC Zaire 264 187 71
2007 Uganda Bundibugyo 149 37 25
2008 DRC Zaire 32 15 47
2011 Uganda Sudan 1 1 100
2012 Uganda Sudan 24 17 71
2012 DRC Bundibugyo 57 29 51
2012-2013 Uganda Sudan 7 4 57
2014 Guinea, Liberia, 
and Sierra Leone
Zaire 9191 4546 49
2014 DRC Zaire 68 49 72
DRC: Democratic Republic of Congo.
Source: WHO28 and CDC (http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html).
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The mean incubation period for cases of Zaire Ebola virus 
infection due to injection is shorter than contact expo-
sures.46 Also the case fatality rate was greater when the in-
fection was acquired by injection.46
Target cells and tissues
Ebola virus has a broad cell tropism, infecting a wide range 
of cell types. Monocytes, macrophages, dendritic cells, en-
dothelial cells, ibroblasts, hepatocytes, adrenal cortical 
cells, and several types of epithelial cells are capable of vi-
ral replication.40,41,47 Studies in non-human primates experi-
mentally infected with Zaire Ebola virus suggest that 
monocytes, macrophages, and dendritic cells are the early 
and preferred replication sites of these viruses.48 These cells 
seem to have critical roles in dissemination of the virus as it 
spreads from the initial infection site to regional lymph 
nodes, probably through the lymphatic system, and to the 
liver and spleen through the blood.48,49 Monocytes, macro-
phages, and dendritic cells infected with Ebola virus mi-
grate out of the spleen and lymph nodes to other tissues 
disseminating the infection.50,51
Ebola virus’ glycoprotein may be the primary determinant 
of vascular-cell injury, therefore infection of endothelial 
cells induces structural damage, which could contribute to 
the hemorrhagic diathesis.52 However histological analysis 
of autopsy tissue did not identify vascular lesions in early 
outbreaks and no vascular lesions in any subsequent studies 
have been reported.53
Liver and adrenal glands seem to be important targets for 
Ebola viruses. Various degrees of hepatocellular necrosis have 
been reported, but the lesions are not serious enough to ex-
plain the cause of death.10,41,47,53 The severe hepatocellular 
necrosis can explain the hemorrhagic tendencies because of 
the decreased synthesis of coagulation factors. As the adre-
nal cortex controls blood pressure homeostasis, impaired se-
cretion of enzymes due to adrenal infection and necrosis 
leads to hypotension and sodium loss with hypovolemia.10,41
During Ebola virus infection, there is a lymphoid depletion 
and necrosis in patients with fatal disease and in non-human 
primates experimentally infected.51,54 Curiously, Ebola virus 
does not infect lymphocytes and the loss is due to lympho-
cyte apoptosis.55,56 The mechanism is not known, but it could 
involve the TNF-related apoptosis-inducing ligand (TRAIL) 
and Fas death receptor pathway.41,57
Host immune response
Ebola virus infection triggers the expression of several in-
lammatory mediators including interferon, interleukins 2, 6, 
8, and 10, interferon-inducible protein 10, monocyte che-
moattractant protein 1, regulated upon activation, normal 
T cell expressed and secreted (RANTES), TNFα, and reactive 
oxygen and nitrogen species.10,55,57-59 Virus-induced expres-
sion of these mediators produces an immunological imbal-
ance that contributes to the progression of the disease. It 
was shown that a deregulated proinlammatory response re-
sulted in fatal cases and well-regulated inflammatory re-
sponses were associated with recovery.58
Inhibition of the type I interferon response seems to be a 
key feature of filovirus pathogenesis.60,61 The Ebola virus 
VP35 works as a type I interferon antagonist15 by blocking 
activation of interferon regulatory factor 3 and possibly by 
preventing transcription of interferon β.62 Additionally, oth-
er studies suggest that expression of VP24 of the Ebola virus 
interferes with type I interferon signaling.14,63 Mutations in 
VP24 have been linked to adaptation of Zaire Ebola virus to 
produce lethal disease in mice64 and guineapigs.65
Clinical manifestations
The different species of Ebola virus seems to cause different 
clinical manifestations, but close observation of the diseases 
under good conditions has been rare. Generally the incuba-
tion period of EVD consists of 2-21 days (mean, 4-10).50 In 
contrast, the recent outbreak has a mean incubation period 
of 11.4 days and did not vary by country.66 The onset of symp-
toms is abrupt and starts with fever, chills, malaise and myal-
gia. The following symptoms indicate multisystem 
involvement and include: systemic (prostration); gastrointes-
tinal (anorexia, nausea, vomiting, abdominal pain, diarrhea), 
respiratory (chest pain, dyspnea, cough, nasal discharge), 
vascular (conjunctival injection, postural hypotension, ede-
ma), and neurological (headache, confusion, coma) manifes-
tations. Hemorrhagic manifestations arise during the peak of 
the illness and include petechiae, ecchymosis, uncontrolled 
oozing from venipuncture sites, mucosal hemorrhages, and 
post-mortem evidence of visceral hemorrhagic effusions.50 In 
the recent outbreak in West Africa, the most common symp-
toms were fever (87.1%), fatigue (76.4%), vomiting (67.6%), 
diarrhea (65.6%), anorexia (64.5%), headache (53.4%), and 
abdominal pain (44.3%).66 Specific hemorrhagic symptoms 
were rarely reported (<1-5.7%) but unexplained bleeding was 
reported in 18% of the cases.66 Regarding DRC outbreak, the 
most common symptoms were the same as the West African 
outbreak with almost similar proportions: fever (92%), fa-
tigue (71%), vomiting (47%), diarrhea (68%), anorexia (39%), 
headache (45%), and abdominal pain (47%).26
Patients with fatal disease develop clinical signs early 
during infection and die typically between day 6 and 16, 
due to hypovolemic shock and multiorgan failure. Hemor-
rhages can be severe but are only present in fewer than half 
of patients. In non-fatal cases, patients have fever for sev-
eral days and improve typically around day 6-11, about the 
time that the humoral antibody response is observed.10,38
Laboratory indings
Laboratory indings are less characteristic, but the following 
indings can be associated with EVD: early leucopenia (1000 
cells/µL) with lymphopenia and subsequent neutrophilia, 
presence of atypical lymphocytes, thrombocytopenia 
(50,000-100,000 cells/µL), highly raised serum aminotrans-
ferase concentrations (aspartate aminotransferase exceed-
ing alanine aminotransferase), hyperproteinemia, and 
proteinuria. Prothrombin and partial thromboplastin times 
are extended and ibrin split products are detectable.10
Diagnosis
The diagnosis can be dificult in a recent infection, because 
early symptoms are non-speciic to EVD and are often seen 
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in patients with more common diseases such as malaria, ty-
phoid fever and dengue fever. The algorithm shown on ig-
ure 1 could be helpful when evaluating the patient.67 The 
diagnostic conirmation can be made with the following pro-
cedures: antibody-capture enzyme-linked immunosorbent 
assay (ELISA),68,69 antigen-capture detection tests, serum 
neutralization test, reverse transcriptase polymerase chain 
reaction (RT-PCR) assay,70,71 electron microscopy,72,73 and vi-
rus isolation by cell culture.28,74
Viral antigen/nucleic acid can be detected in blood from 
3 up to 16 days post onset of symptoms.75 IgM antibodies can 
appear as early as 2 days post onset of symptoms and disap-
pear between 30 and 168 days after infection. IgG-speciic 
antibodies develop between days 6 and 18 after onset and 
persist for many years.75,76 All the diagnostic procedures 
should be done in BSL-4 laboratory, unless the samples are 
inactivated with gamma radiation by exposure to a co-
balt-60 source77 or guanidinium isothiocyanate in case of 
nucleic acid extraction.78 These methods of inactivation al-
low the safe manipulation of material outside the contain-
ment laboratory.
Treatment
There is no speciic treatment for EVD. Present strategies 
are mainly symptomatic and supportive.50 The goals of 
treatment are: volume repletion, maintenance of blood 
pressure (with vasopressors if needed), maintenance of oxy-
Figure 1 Algorithm for Evalua-
tion of the Returned Traveler.
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genation, pain control, nutritional support, treatment of 
secondary bacterial infections and preexisting conditions. 
Likewise, the treatment must provide supportive care for 
complications, such as hypovolemia, electrolyte abnormali-
ties, refractory shock, hypoxemia, hemorrhage, septic 
shock, multiorgan failure, and disseminated intravascular 
coagulation.28,79,80
Progress has been made in new experimental approaches 
to post exposure prophylaxis and/or treatment that are ef-
fective in laboratory primates. There are several therapeu-
tic candidates in study.81-83 Plasma, whole blood and other 
blood-derived components from convalescent patients have 
theoretical and anecdotal evidence that can improve sur-
vival in a small group of EVD cases.84,85 ZMapp, monoclonal 
antibodies against Ebola made in plants, has been already 
used in a few patients with EVD. However, the number of 
treated patients is too small to evaluate safety and efica-
cy.82,83,86 Other potential therapeutics under development 
include: T-750 (favipiravir) is a pyrazine carboxamide de-
rivative that inhibits the viral RNA-dependent RNA poly-
merase or induce lethal mutagenesis by incorporating into 
the viral RNA.87 BCX-4430, a new nucleotide analogue, in-
hibits virus replication by inhibiting viral RNA polymerase 
function.88 RNA based drugs as small interfering RNAs and 
phosphomorpholino oligonucleotides may effectively pre-
vent EVD in nonhuman primates by targeting the Zaire Ebola 
virus RNA polymerase L protein.89 Nematode-derived antico-
agulation protein, rNAPc2, plays an important role in weak-
ening coagulation and inlammation.90 Some of these have 
demonstrated safety in humans and eficacy in animal mod-
els, however clinical evaluation will be required to deter-
mine whether they are eficacious in EVD and whether they 
are safe at the doses required.82 In addition to these novel 
products, there are also several existing medicines that 
have been approved for treatment of other diseases and 
conditions but which may be re-purposed for EVD.82,91,92
Prevention
It is not always possible to identify patients with EVD early 
in the course of their illness because initial symptoms may 
be non-speciic. For this reason, it is important that HCW at 
all levels carefully apply standard precautions on a consis-
tent basis, with all patients in every practice and at all 
times.93 These include: hand hygiene; use of disposable 
medical examination gloves before contact with body luids, 
mucous membrane, non-intact skin and contaminated 
items, and gown and eye protection before procedures and 
patient-care activities likely to involve contact with or pro-
jection of blood or body luids. In addition, regular applica-
tion of best practices for injection safety and safe handling 
and disposal of sharp instruments, safe cleaning and disin-
fection of the environment and of reusable equipment, and 
safe laundry and waste management should be a high prior-
ity in the health care facility.6,28,94
Suspected or conirmed cases should be placed in single 
isolation rooms with an adjoining dedicated toilet or la-
trine, showers, sink equipped with running water, soap and 
single-use towels, alcohol-based hand rub dispensers, stocks 
of personal protective equipment (PPE), stocks of medi-
cines, good ventilation, screened windows, doors closed and 
restricted access.95,96 If isolation rooms are unavailable, co-
hort these patients in speciic conined areas while rigor-
ously keeping suspected and conirmed cases separate and 
ensure the items listed here for isolation rooms are readily 
available. Make sure that there is at least 1 meter distance 
between patient beds.95,96 Before entering care areas, every 
HCW should don personal protection equipment (PPE) ac-
cording to the expected level of risk and following the steps 
recommended by WHO.94 The PPE include: gloves, an imper-
meable long-sleeve gown, boots/closed-toe shoes with 
overshoes, and a mask and eye protection for splashes. Af-
ter exiting care areas, perform careful removal of PPE to 
avoid contamination of any area of the face (i.e. eyes, nose, 
or mouth) or non-intact skin.94,95
People with percutaneous or muco-cutaneous exposure to 
blood, body luids, secretions, or excretions from a patient 
with suspected or conirmed EVD should immediately and 
safely stop any current tasks, leave the patient care area, 
and safely remove PPE. Immediately after leaving the pa-
tient care area, wash the affected skin surfaces or the per-
cutaneous injury site with soap and water. Irrigate mucous 
membranes with copious amounts of water or an eyewash 
solution, and not with chlorine solutions or other disinfec-
tants. The incident should be immediately reported to the 
local coordinator. Exposed persons should be medically 
evaluated including for other potential exposures and re-
ceive follow-up care, including fever monitoring twice daily 
for 21 days after the incident.95,97
Transmission of the virus to the HCW has been document-
ed in most of the outbreaks and has been a sometimes exag-
gerated concern. A recent review of the human to human 
transmission shows that most of the cases in HCW occurred 
due to the lack of and/or the inappropriate use of the pro-
tective equipment and that with the appropriate use of the 
equipment transmission rarely happened.94-97 As October 
20th, 2014 the CDC tightened the recommendations for pre-
vention of transmission to the HCW including more careful 
protocols for dressing and undressing, including a monitor 
for the process94-97.
Vaccines
There are two promising candidate vaccines that have clini-
cal-grade vials available for phase 1 pre-licensure clinical 
trials.98,99 The irst vaccine (cAd3-ZEBOV) was developed by 
GlaxoSmithKline in collaboration with the US National Insti-
tute of Allergy and Infectious Diseases. It uses a chimpan-
zee-derived adenovirus vector with the Zaire Ebola virus GP 
gene inserted.100 The second (rVSV-ZEBOV) was developed 
by the Public Health Agency of Canada in Winnipeg. The 
vaccine uses an attenuated or weakened vesicular stomati-
tis virus expressing the different Ebola virus GP gene.101 Two 
phase 1 trials of the cAd3-ZEBOV started in September 2014 
in USA and UK, and the irst phase 1 trial of VSV-ZEBOV is 
due to start early in October in USA.82,99
Economical aspects in West Africa EVD 
outbreak
In Guinea, Sierra Leone and Liberia, where widespread and 
intense transmission of EVD is occurring, medical doctors are 
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scarce and governmental health expenses are low.102-104 That 
can be translated to inadequate and insuficient health care. 
Health care infrastructure is inadequate, and health workers 
and essential supplies including personal protective equip-
ment are scarce. Complicated patients could not be ade-
quately treated and decease and the lack of suficient and 
isolated beds can spread the disease to the rest of the com-
munity. These countries were already handling major health 
challenges, like malaria and other endemic diseases, and 
were not prepared for EVD. These countries’ borders are po-
rous, and movement between them is constant. Traditional 
practices, such as bathing of corpses before burial, have fa-
cilitated transmission. Decades of conlict have left the pop-
ulations distrustful of governing oficials and authority igures 
such as health professionals.105,106 This contributed to the 
vandalizing of health clinics and even the “rescue” of sick 
patients from the clinics, spreading the disease. As a conse-
quence, the outbreak could not be contained and spread 
from Guinea to Liberia, Sierra Leone, Nigeria and Senegal.29
Conclusions
Although the current epidemic of EVD in West Africa is un-
precedented in scale, the clinical course of infection and 
the transmissibility of the virus are similar to those in previ-
ous EVD outbreaks.107 This epidemic is exceptionally large, 
not predominantly because of the biologic characteristics of 
the virus, but rather because of the attributes of the af-
fected populations and because control efforts have been 
insuficient to halt the spread of infection. The HCW should 
be alert, well informed, and ready for action in case a pa-
tient arrives with EVD symptomatology. 
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